-
1
-
-
84928917822
-
Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
-
Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Patt D., Chen T.T., Berman D.M., Wolchok J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015, 33:1889-1894.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1889-1894
-
-
Schadendorf, D.1
Hodi, F.S.2
Robert, C.3
Weber, J.S.4
Margolin, K.5
Hamid, O.6
Patt, D.7
Chen, T.T.8
Berman, D.M.9
Wolchok, J.D.10
-
2
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
Schadendorf, D.7
Dummer, R.8
Smylie, M.9
Rutkowski, P.10
-
3
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
-
(2013)
N Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
Segal, N.H.7
Ariyan, C.E.8
Gordon, R.A.9
Reed, K.10
-
4
-
-
84944937210
-
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
-
Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Chow L.Q., Vokes E.E., Felip E., Holgado E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015, 373:1627-1639.
-
(2015)
N Engl J Med
, vol.373
, pp. 1627-1639
-
-
Borghaei, H.1
Paz-Ares, L.2
Horn, L.3
Spigel, D.R.4
Steins, M.5
Ready, N.E.6
Chow, L.Q.7
Vokes, E.E.8
Felip, E.9
Holgado, E.10
-
5
-
-
84923078390
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
-
Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014, 515:558-562.
-
(2014)
Nature
, vol.515
, pp. 558-562
-
-
Powles, T.1
Eder, J.P.2
Fine, G.D.3
Braiteh, F.S.4
Loriot, Y.5
Cruz, C.6
Bellmunt, J.7
Burris, H.A.8
Petrylak, D.P.9
Teng, S.L.10
-
6
-
-
84932628341
-
PD-1 blockade in tumors with mismatch-repair deficiency
-
Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015, 372:2509-2520.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
Bartlett, B.R.4
Kemberling, H.5
Eyring, A.D.6
Skora, A.D.7
Luber, B.S.8
Azad, N.S.9
Laheru, D.10
-
7
-
-
84857725402
-
Exploiting the mutanome for tumor vaccination
-
Castle J.C., Kreiter S., Diekmann J., Lower M., van de Roemer N., de Graaf J., Selmi A., Diken M., Boegel S., Paret C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
-
(2012)
Cancer Res
, vol.72
, pp. 1081-1091
-
-
Castle, J.C.1
Kreiter, S.2
Diekmann, J.3
Lower, M.4
van de Roemer, N.5
de Graaf, J.6
Selmi, A.7
Diken, M.8
Boegel, S.9
Paret, C.10
-
8
-
-
84899836282
-
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
-
Brown S.D., Warren R.L., Gibb E.A., Martin S.D., Spinelli J.J., Nelson B.H., Holt R.A. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014, 24:743-750.
-
(2014)
Genome Res
, vol.24
, pp. 743-750
-
-
Brown, S.D.1
Warren, R.L.2
Gibb, E.A.3
Martin, S.D.4
Spinelli, J.J.5
Nelson, B.H.6
Holt, R.A.7
-
9
-
-
84928761118
-
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348:124-128.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
Lee, W.7
Yuan, J.8
Wong, P.9
Ho, T.S.10
-
10
-
-
84918828514
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma
-
Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014, 371:2189-2199.
-
(2014)
N Engl J Med
, vol.371
, pp. 2189-2199
-
-
Snyder, A.1
Makarov, V.2
Merghoub, T.3
Yuan, J.4
Zaretsky, J.M.5
Desrichard, A.6
Walsh, L.A.7
Postow, M.A.8
Wong, P.9
Ho, T.S.10
-
11
-
-
82255164138
-
Towards a systems understanding of MHC class I and MHC class II antigen presentation
-
Neefjes J., Jongsma M.L., Paul P., Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011, 11:823-836.
-
(2011)
Nat Rev Immunol
, vol.11
, pp. 823-836
-
-
Neefjes, J.1
Jongsma, M.L.2
Paul, P.3
Bakke, O.4
-
12
-
-
84964913796
-
Analysis of MHC immunopeptidomes using mass spectrometry
-
Caron E., Kowalewski D.J., Koh C.C., Sturm T., Schuster H., Aebersold R. Analysis of MHC immunopeptidomes using mass spectrometry. Mol Cell Proteomics 2015.
-
(2015)
Mol Cell Proteomics
-
-
Caron, E.1
Kowalewski, D.J.2
Koh, C.C.3
Sturm, T.4
Schuster, H.5
Aebersold, R.6
-
13
-
-
84927040395
-
Exploration of peptides bound to MHC class I molecules in melanoma
-
Pritchard A.L., Hastie M.L., Neller M., Gorman J.J., Schmidt C.W., Hayward N.K. Exploration of peptides bound to MHC class I molecules in melanoma. Pigment Cell Melanoma Res 2015, 28:281-294.
-
(2015)
Pigment Cell Melanoma Res
, vol.28
, pp. 281-294
-
-
Pritchard, A.L.1
Hastie, M.L.2
Neller, M.3
Gorman, J.J.4
Schmidt, C.W.5
Hayward, N.K.6
-
14
-
-
84866914575
-
High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells
-
Jarmalavicius S., Welte Y., Walden P. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells. J Biol Chem 2012, 287:33401-33411.
-
(2012)
J Biol Chem
, vol.287
, pp. 33401-33411
-
-
Jarmalavicius, S.1
Welte, Y.2
Walden, P.3
-
15
-
-
84924326106
-
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation
-
Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics 2015, 14:658-673.
-
(2015)
Mol Cell Proteomics
, vol.14
, pp. 658-673
-
-
Bassani-Sternberg, M.1
Pletscher-Frankild, S.2
Jensen, L.J.3
Mann, M.4
-
16
-
-
84942370351
-
T cells engineered to express a T-cell receptor specific for glypican recognize and kill hepatoma cells in vitro and in mice
-
Dargel C., Bassani-Sternberg M., Hasreiter J., Zani F., Bockmann J.H., Thiele F., Bohne F., Wisskirchen K., Wilde S., Sprinzl M.F., et al. T cells engineered to express a T-cell receptor specific for glypican recognize and kill hepatoma cells in vitro and in mice. Gastroenterology 2015.
-
(2015)
Gastroenterology
-
-
Dargel, C.1
Bassani-Sternberg, M.2
Hasreiter, J.3
Zani, F.4
Bockmann, J.H.5
Thiele, F.6
Bohne, F.7
Wisskirchen, K.8
Wilde, S.9
Sprinzl, M.F.10
-
17
-
-
0037108856
-
Integrated functional genomics approach for the design of patient-individual antitumor vaccines
-
Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., Kurek R., Loeser W., Bichler K.H., Wernet D., et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002, 62:5818-5827.
-
(2002)
Cancer Res
, vol.62
, pp. 5818-5827
-
-
Weinschenk, T.1
Gouttefangeas, C.2
Schirle, M.3
Obermayr, F.4
Walter, S.5
Schoor, O.6
Kurek, R.7
Loeser, W.8
Bichler, K.H.9
Wernet, D.10
-
18
-
-
1542267730
-
The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy
-
Singh-Jasuja H., Emmerich N.P., Rammensee H.G. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004, 53:187-195.
-
(2004)
Cancer Immunol Immunother
, vol.53
, pp. 187-195
-
-
Singh-Jasuja, H.1
Emmerich, N.P.2
Rammensee, H.G.3
-
19
-
-
84860209098
-
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
-
Dutoit V., Herold-Mende C., Hilf N., Schoor O., Beckhove P., Bucher J., Dorsch K., Flohr S., Fritsche J., Lewandrowski P., et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012, 135:1042-1054.
-
(2012)
Brain
, vol.135
, pp. 1042-1054
-
-
Dutoit, V.1
Herold-Mende, C.2
Hilf, N.3
Schoor, O.4
Beckhove, P.5
Bucher, J.6
Dorsch, K.7
Flohr, S.8
Fritsche, J.9
Lewandrowski, P.10
-
20
-
-
85027913587
-
Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy
-
Berlin C., Kowalewski D.J., Schuster H., Mirza N., Walz S., Handel M., Schmid-Horch B., Salih H.R., Kanz L., Rammensee H.G., et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 2014.
-
(2014)
Leukemia
-
-
Berlin, C.1
Kowalewski, D.J.2
Schuster, H.3
Mirza, N.4
Walz, S.5
Handel, M.6
Schmid-Horch, B.7
Salih, H.R.8
Kanz, L.9
Rammensee, H.G.10
-
21
-
-
84942525157
-
The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy
-
Walz S., Stickel J.S., Kowalewski D.J., Schuster H., Weisel K., Backert L., Kahn S., Nelde A., Stroh T., Handel M., et al. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood 2015, 126:1203-1213.
-
(2015)
Blood
, vol.126
, pp. 1203-1213
-
-
Walz, S.1
Stickel, J.S.2
Kowalewski, D.J.3
Schuster, H.4
Weisel, K.5
Backert, L.6
Kahn, S.7
Nelde, A.8
Stroh, T.9
Handel, M.10
-
22
-
-
78650443580
-
Soluble plasma HLA peptidome as a potential source for cancer biomarkers
-
Bassani-Sternberg M., Barnea E., Beer I., Avivi I., Katz T., Admon A. Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A 2010, 107:18769-18776.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 18769-18776
-
-
Bassani-Sternberg, M.1
Barnea, E.2
Beer, I.3
Avivi, I.4
Katz, T.5
Admon, A.6
-
23
-
-
0028800987
-
HLA-A2 subtypes are functionally distinct in peptide binding and presentation
-
Barouch D., Friede T., Stevanovic S., Tussey L., Smith K., Rowland-Jones S., Braud V., McMichael A., Rammensee H.G. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med 1995, 182:1847-1856.
-
(1995)
J Exp Med
, vol.182
, pp. 1847-1856
-
-
Barouch, D.1
Friede, T.2
Stevanovic, S.3
Tussey, L.4
Smith, K.5
Rowland-Jones, S.6
Braud, V.7
McMichael, A.8
Rammensee, H.G.9
-
24
-
-
84896980006
-
Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD)
-
Mommen G.P., Frese C.K., Meiring H.D., van Gaans-van den Brink J., de Jong A.P., van Els C.A., Heck A.J. Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD). Proc Natl Acad Sci U S A 2014, 111:4507-4512.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, pp. 4507-4512
-
-
Mommen, G.P.1
Frese, C.K.2
Meiring, H.D.3
van Gaans-van den Brink, J.4
de Jong, A.P.5
van Els, C.A.6
Heck, A.J.7
-
25
-
-
84928195112
-
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
-
Carreno B.M., Magrini V., Becker-Hapak M., Kaabinejadian S., Hundal J., Petti A.A., Ly A., Lie W.R., Hildebrand W.H., Mardis E.R., et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348:803-808.
-
(2015)
Science
, vol.348
, pp. 803-808
-
-
Carreno, B.M.1
Magrini, V.2
Becker-Hapak, M.3
Kaabinejadian, S.4
Hundal, J.5
Petti, A.A.6
Ly, A.7
Lie, W.R.8
Hildebrand, W.H.9
Mardis, E.R.10
-
26
-
-
79956277775
-
Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring
-
Tan C.T., Croft N.P., Dudek N.L., Williamson N.A., Purcell A.W. Direct quantitation of MHC-bound peptide epitopes by selected reaction monitoring. Proteomics 2011, 11:2336-2340.
-
(2011)
Proteomics
, vol.11
, pp. 2336-2340
-
-
Tan, C.T.1
Croft, N.P.2
Dudek, N.L.3
Williamson, N.A.4
Purcell, A.W.5
-
27
-
-
84905406689
-
Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes
-
Hassan C., Kester M.G., Oudgenoeg G., de Ru A.H., Janssen G.M., Drijfhout J.W., Spaapen R.M., Jimenez C.R., Heemskerk M.H., Falkenburg J.H., et al. Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. J Proteomics 2014, 109:240-244.
-
(2014)
J Proteomics
, vol.109
, pp. 240-244
-
-
Hassan, C.1
Kester, M.G.2
Oudgenoeg, G.3
de Ru, A.H.4
Janssen, G.M.5
Drijfhout, J.W.6
Spaapen, R.M.7
Jimenez, C.R.8
Heemskerk, M.H.9
Falkenburg, J.H.10
-
28
-
-
13744260910
-
Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members
-
Hogan K.T., Sutton J.N., Chu K.U., Busby J.A., Shabanowitz J., Hunt D.F., Slingluff C.L. Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunol Immunother 2005, 54:359-371.
-
(2005)
Cancer Immunol Immunother
, vol.54
, pp. 359-371
-
-
Hogan, K.T.1
Sutton, J.N.2
Chu, K.U.3
Busby, J.A.4
Shabanowitz, J.5
Hunt, D.F.6
Slingluff, C.L.7
-
29
-
-
27744527569
-
MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue
-
Kramer B.F., Schoor O., Kruger T., Reichle C., Muller M., Weinschenk T., Hennenlotter J., Stenzl A., Rammensee H.G., Stevanovic S. MAGED4-expression in renal cell carcinoma and identification of an HLA-A*25-restricted MHC class I ligand from solid tumor tissue. Cancer Biol Therapy 2005, 4:943-948.
-
(2005)
Cancer Biol Therapy
, vol.4
, pp. 943-948
-
-
Kramer, B.F.1
Schoor, O.2
Kruger, T.3
Reichle, C.4
Muller, M.5
Weinschenk, T.6
Hennenlotter, J.7
Stenzl, A.8
Rammensee, H.G.9
Stevanovic, S.10
-
30
-
-
84864662070
-
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
-
Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., Staehler M., Brugger W., Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
-
(2012)
Nat Med
, vol.18
, pp. 1254-1261
-
-
Walter, S.1
Weinschenk, T.2
Stenzl, A.3
Zdrojowy, R.4
Pluzanska, A.5
Szczylik, C.6
Staehler, M.7
Brugger, W.8
Dietrich, P.Y.9
Mendrzyk, R.10
-
31
-
-
0037606199
-
Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells
-
Ramakrishna V., Ross M.M., Petersson M., Gatlin C.C., Lyons C.E., Miller C.L., Myers H.E., McDaniel M., Karns L.R., Kiessling R., et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003, 15:751-763.
-
(2003)
Int Immunol
, vol.15
, pp. 751-763
-
-
Ramakrishna, V.1
Ross, M.M.2
Petersson, M.3
Gatlin, C.C.4
Lyons, C.E.5
Miller, C.L.6
Myers, H.E.7
McDaniel, M.8
Karns, L.R.9
Kiessling, R.10
-
32
-
-
84880145306
-
Database of T cell-defined human tumor antigens: the 2013 update
-
Vigneron N., Stroobant V., Van den Eynde B.J., van der Bruggen P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 2013, 13:15.
-
(2013)
Cancer Immun
, vol.13
, pp. 15
-
-
Vigneron, N.1
Stroobant, V.2
Van den Eynde, B.J.3
van der Bruggen, P.4
-
33
-
-
84859399304
-
Dissection of T-cell antigen specificity in human melanoma
-
Andersen R.S., Thrue C.A., Junker N., Lyngaa R., Donia M., Ellebaek E., Svane I.M., Schumacher T.N., Thor Straten P., Hadrup S.R. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012, 72:1642-1650.
-
(2012)
Cancer Res
, vol.72
, pp. 1642-1650
-
-
Andersen, R.S.1
Thrue, C.A.2
Junker, N.3
Lyngaa, R.4
Donia, M.5
Ellebaek, E.6
Svane, I.M.7
Schumacher, T.N.8
Thor Straten, P.9
Hadrup, S.R.10
-
34
-
-
84871482694
-
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
-
Andersen R.S., Kvistborg P., Frosig T.M., Pedersen N.W., Lyngaa R., Bakker A.H., Shu C.J., Straten P., Schumacher T.N., Hadrup S.R. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc 2012, 7:891-902.
-
(2012)
Nat Protoc
, vol.7
, pp. 891-902
-
-
Andersen, R.S.1
Kvistborg, P.2
Frosig, T.M.3
Pedersen, N.W.4
Lyngaa, R.5
Bakker, A.H.6
Shu, C.J.7
Straten, P.8
Schumacher, T.N.9
Hadrup, S.R.10
-
35
-
-
37649021448
-
Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester
-
Quah B.J., Warren H.S., Parish C.R. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 2007, 2:2049-2056.
-
(2007)
Nat Protoc
, vol.2
, pp. 2049-2056
-
-
Quah, B.J.1
Warren, H.S.2
Parish, C.R.3
-
36
-
-
84939876111
-
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining
-
Chudley L., McCann K.J., Coleman A., Cazaly A.M., Bidmon N., Britten C.M., van der Burg S.H., Gouttefangeas C., Jandus C., Laske K., et al. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother 2014, 63:1199-1211.
-
(2014)
Cancer Immunol Immunother
, vol.63
, pp. 1199-1211
-
-
Chudley, L.1
McCann, K.J.2
Coleman, A.3
Cazaly, A.M.4
Bidmon, N.5
Britten, C.M.6
van der Burg, S.H.7
Gouttefangeas, C.8
Jandus, C.9
Laske, K.10
-
37
-
-
42549138499
-
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
-
Melief C.J., van der Burg S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008, 8:351-360.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 351-360
-
-
Melief, C.J.1
van der Burg, S.H.2
-
38
-
-
84875689800
-
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
-
van Poelgeest M.I., Welters M.J., van Esch E.M., Stynenbosch L.F., Kerpershoek G., van Persijn van Meerten E.L., van den Hende M., Lowik M.J., Berends-van der Meer D.M., Fathers L.M., et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013, 11:88.
-
(2013)
J Transl Med
, vol.11
, pp. 88
-
-
van Poelgeest, M.I.1
Welters, M.J.2
van Esch, E.M.3
Stynenbosch, L.F.4
Kerpershoek, G.5
van Persijn van Meerten, E.L.6
van den Hende, M.7
Lowik, M.J.8
Berends-van der Meer, D.M.9
Fathers, L.M.10
-
39
-
-
84894553314
-
Trial watch: peptide vaccines in cancer therapy
-
Aranda F., Vacchelli E., Eggermont A., Galon J., Sautes-Fridman C., Tartour E., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013, 2:e2662.
-
(2013)
Oncoimmunology
, vol.2
, pp. e2662
-
-
Aranda, F.1
Vacchelli, E.2
Eggermont, A.3
Galon, J.4
Sautes-Fridman, C.5
Tartour, E.6
Zitvogel, L.7
Kroemer, G.8
Galluzzi, L.9
-
40
-
-
84921818011
-
IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer
-
Kirner A., Mayer-Mokler A., Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother 2014, 10:3179-3189.
-
(2014)
Hum Vaccin Immunother
, vol.10
, pp. 3179-3189
-
-
Kirner, A.1
Mayer-Mokler, A.2
Reinhardt, C.3
-
41
-
-
0036645058
-
+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design
-
+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002, 62:3630-3635.
-
(2002)
Cancer Res
, vol.62
, pp. 3630-3635
-
-
Zeng, G.1
Li, Y.2
El-Gamil, M.3
Sidney, J.4
Sette, A.5
Wang, R.F.6
Rosenberg, S.A.7
Robbins, P.F.8
-
42
-
-
84997666967
-
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
-
Kubler H., Scheel B., Gnad-Vogt U., Miller K., Schultze-Seemann W., Vom Dorp F., Parmiani G., Hampel C., Wedel S., Trojan L., et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 2015, 3:26.
-
(2015)
J Immunother Cancer
, vol.3
, pp. 26
-
-
Kubler, H.1
Scheel, B.2
Gnad-Vogt, U.3
Miller, K.4
Schultze-Seemann, W.5
Vom Dorp, F.6
Parmiani, G.7
Hampel, C.8
Wedel, S.9
Trojan, L.10
-
43
-
-
84902593489
-
Trial watch: DNA vaccines for cancer therapy
-
Pol J., Bloy N., Obrist F., Eggermont A., Galon J., Herve Fridman W., Cremer I., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014, 3:e28185.
-
(2014)
Oncoimmunology
, vol.3
, pp. e28185
-
-
Pol, J.1
Bloy, N.2
Obrist, F.3
Eggermont, A.4
Galon, J.5
Herve Fridman, W.6
Cremer, I.7
Zitvogel, L.8
Kroemer, G.9
Galluzzi, L.10
-
44
-
-
84866458433
-
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial
-
Oshita C., Takikawa M., Kume A., Miyata H., Ashizawa T., Iizuka A., Kiyohara Y., Yoshikawa S., Tanosaki R., Yamazaki N., et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012, 28:1131-1138.
-
(2012)
Oncol Rep
, vol.28
, pp. 1131-1138
-
-
Oshita, C.1
Takikawa, M.2
Kume, A.3
Miyata, H.4
Ashizawa, T.5
Iizuka, A.6
Kiyohara, Y.7
Yoshikawa, S.8
Tanosaki, R.9
Yamazaki, N.10
-
45
-
-
34547915603
-
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer
-
Odunsi K., Qian F., Matsuzaki J., Mhawech-Fauceglia P., Andrews C., Hoffman E.W., Pan L., Ritter G., Villella J., Thomas B., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007, 104:12837-12842.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 12837-12842
-
-
Odunsi, K.1
Qian, F.2
Matsuzaki, J.3
Mhawech-Fauceglia, P.4
Andrews, C.5
Hoffman, E.W.6
Pan, L.7
Ritter, G.8
Villella, J.9
Thomas, B.10
-
46
-
-
0034331218
-
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
-
Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96:3102-3108.
-
(2000)
Blood
, vol.96
, pp. 3102-3108
-
-
Brossart, P.1
Wirths, S.2
Stuhler, G.3
Reichardt, V.L.4
Kanz, L.5
Brugger, W.6
-
47
-
-
84871943629
-
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination
-
Aarntzen E.H., De Vries I.J., Lesterhuis W.J., Schuurhuis D., Jacobs J.F., Bol K., Schreibelt G., Mus R., De Wilt J.H., Haanen J.B., et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013, 73:19-29.
-
(2013)
Cancer Res
, vol.73
, pp. 19-29
-
-
Aarntzen, E.H.1
De Vries, I.J.2
Lesterhuis, W.J.3
Schuurhuis, D.4
Jacobs, J.F.5
Bol, K.6
Schreibelt, G.7
Mus, R.8
De Wilt, J.H.9
Haanen, J.B.10
-
48
-
-
84938963928
-
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
-
Rapoport A.P., Stadtmauer E.A., Binder-Scholl G.K., Goloubeva O., Vogl D.T., Lacey S.F., Badros A.Z., Garfall A., Weiss B., Finklestein J., et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015, 21:914-921.
-
(2015)
Nat Med
, vol.21
, pp. 914-921
-
-
Rapoport, A.P.1
Stadtmauer, E.A.2
Binder-Scholl, G.K.3
Goloubeva, O.4
Vogl, D.T.5
Lacey, S.F.6
Badros, A.Z.7
Garfall, A.8
Weiss, B.9
Finklestein, J.10
-
49
-
-
79952187823
-
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
-
Parkhurst M.R., Yang J.C., Langan R.C., Dudley M.E., Nathan D.A., Feldman S.A., Davis J.L., Morgan R.A., Merino M.J., Sherry R.M., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Therapy 2011, 19:620-626.
-
(2011)
Mol Therapy
, vol.19
, pp. 620-626
-
-
Parkhurst, M.R.1
Yang, J.C.2
Langan, R.C.3
Dudley, M.E.4
Nathan, D.A.5
Feldman, S.A.6
Davis, J.L.7
Morgan, R.A.8
Merino, M.J.9
Sherry, R.M.10
-
50
-
-
70149114880
-
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
-
Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
-
(2009)
Blood
, vol.114
, pp. 535-546
-
-
Johnson, L.A.1
Morgan, R.A.2
Dudley, M.E.3
Cassard, L.4
Yang, J.C.5
Hughes, M.S.6
Kammula, U.S.7
Royal, R.E.8
Sherry, R.M.9
Wunderlich, J.R.10
-
51
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
52
-
-
84893340488
-
Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue
-
Marcilla M., Alpizar A., Lombardia M., Ramos-Fernandez A., Ramos M., Albar J.P. Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue. Mol Cell Proteomics 2014, 13:462-474.
-
(2014)
Mol Cell Proteomics
, vol.13
, pp. 462-474
-
-
Marcilla, M.1
Alpizar, A.2
Lombardia, M.3
Ramos-Fernandez, A.4
Ramos, M.5
Albar, J.P.6
-
53
-
-
84940552740
-
Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry
-
Abelin J.G., Trantham P.D., Penny S.A., Patterson A.M., Ward S.T., Hildebrand W.H., Cobbold M., Bai D.L., Shabanowitz J., Hunt D.F. Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. Nat Protoc 2015, 10:1308-1318.
-
(2015)
Nat Protoc
, vol.10
, pp. 1308-1318
-
-
Abelin, J.G.1
Trantham, P.D.2
Penny, S.A.3
Patterson, A.M.4
Ward, S.T.5
Hildebrand, W.H.6
Cobbold, M.7
Bai, D.L.8
Shabanowitz, J.9
Hunt, D.F.10
-
54
-
-
84884683734
-
MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia
-
Cobbold M., De La Pena H., Norris A., Polefrone J.M., Qian J., English A.M., Cummings K.L., Penny S., Turner J.E., Cottine J., et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci Transl Med 2013, 5:203ra125.
-
(2013)
Sci Transl Med
, vol.5
, pp. 203ra125
-
-
Cobbold, M.1
De La Pena, H.2
Norris, A.3
Polefrone, J.M.4
Qian, J.5
English, A.M.6
Cummings, K.L.7
Penny, S.8
Turner, J.E.9
Cottine, J.10
-
55
-
-
84941006814
-
Extended O-GlcNAc on HLA class-I-bound peptides
-
Marino F., Bern M., Mommen G.P., Leney A.C., van Gaans-van den Brink J.A., Bonvin A.M., Becker C., van Els C.A., Heck A.J. Extended O-GlcNAc on HLA class-I-bound peptides. J Am Chem Soc 2015, 137:10922-10925.
-
(2015)
J Am Chem Soc
, vol.137
, pp. 10922-10925
-
-
Marino, F.1
Bern, M.2
Mommen, G.P.3
Leney, A.C.4
van Gaans-van den Brink, J.A.5
Bonvin, A.M.6
Becker, C.7
van Els, C.A.8
Heck, A.J.9
-
56
-
-
65249117852
-
N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase
-
Ostankovitch M., Altrich-Vanlith M., Robila V., Engelhard V.H. N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase. J Immunol 2009, 182:4830-4835.
-
(2009)
J Immunol
, vol.182
, pp. 4830-4835
-
-
Ostankovitch, M.1
Altrich-Vanlith, M.2
Robila, V.3
Engelhard, V.H.4
-
57
-
-
0033563771
-
Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells
-
Hiltbold E.M., Alter M.D., Ciborowski P., Finn O.J. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol 1999, 194:143-149.
-
(1999)
Cell Immunol
, vol.194
, pp. 143-149
-
-
Hiltbold, E.M.1
Alter, M.D.2
Ciborowski, P.3
Finn, O.J.4
-
58
-
-
74849135762
-
Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis
-
Feitsma A.L., van der Voort E.I., Franken K.L., el Bannoudi H., Elferink B.G., Drijfhout J.W., Huizinga T.W., de Vries R.R., Toes R.E., Ioan-Facsinay A. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:117-125.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 117-125
-
-
Feitsma, A.L.1
van der Voort, E.I.2
Franken, K.L.3
el Bannoudi, H.4
Elferink, B.G.5
Drijfhout, J.W.6
Huizinga, T.W.7
de Vries, R.R.8
Toes, R.E.9
Ioan-Facsinay, A.10
-
59
-
-
84888116736
-
A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis
-
Scally S.W., Petersen J., Law S.C., Dudek N.L., Nel H.J., Loh K.L., Wijeyewickrema L.C., Eckle S.B., van Heemst J., Pike R.N., et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013, 210:2569-2582.
-
(2013)
J Exp Med
, vol.210
, pp. 2569-2582
-
-
Scally, S.W.1
Petersen, J.2
Law, S.C.3
Dudek, N.L.4
Nel, H.J.5
Loh, K.L.6
Wijeyewickrema, L.C.7
Eckle, S.B.8
van Heemst, J.9
Pike, R.N.10
-
60
-
-
0001433072
-
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
-
Skipper J.C., Hendrickson R.C., Gulden P.H., Brichard V., Van Pel A., Chen Y., Shabanowitz J., Wolfel T., Slingluff C.L., Boon T., et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996, 183:527-534.
-
(1996)
J Exp Med
, vol.183
, pp. 527-534
-
-
Skipper, J.C.1
Hendrickson, R.C.2
Gulden, P.H.3
Brichard, V.4
Van Pel, A.5
Chen, Y.6
Shabanowitz, J.7
Wolfel, T.8
Slingluff, C.L.9
Boon, T.10
-
61
-
-
33749512798
-
Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases
-
Altrich-VanLith M.L., Ostankovitch M., Polefrone J.M., Mosse C.A., Shabanowitz J., Hunt D.F., Engelhard V.H. Processing of a class I-restricted epitope from tyrosinase requires peptide N-glycanase and the cooperative action of endoplasmic reticulum aminopeptidase 1 and cytosolic proteases. J Immunol 2006, 177:5440-5450.
-
(2006)
J Immunol
, vol.177
, pp. 5440-5450
-
-
Altrich-VanLith, M.L.1
Ostankovitch, M.2
Polefrone, J.M.3
Mosse, C.A.4
Shabanowitz, J.5
Hunt, D.F.6
Engelhard, V.H.7
-
62
-
-
48449106045
-
NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11
-
Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 2008, 36:W509-W512.
-
(2008)
Nucleic Acids Res
, vol.36
, pp. W509-W512
-
-
Lundegaard, C.1
Lamberth, K.2
Harndahl, M.3
Buus, S.4
Lund, O.5
Nielsen, M.6
-
63
-
-
39549084433
-
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence
-
Nielsen M., Lundegaard C., Blicher T., Lamberth K., Harndahl M., Justesen S., Roder G., Peters B., Sette A., Lund O., et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS ONE 2007, 2:e796.
-
(2007)
PLoS ONE
, vol.2
, pp. e796
-
-
Nielsen, M.1
Lundegaard, C.2
Blicher, T.3
Lamberth, K.4
Harndahl, M.5
Justesen, S.6
Roder, G.7
Peters, B.8
Sette, A.9
Lund, O.10
-
64
-
-
84946076702
-
The immune epitope database (IEDB) 3.0
-
Vita R., Overton J.A., Greenbaum J.A., Ponomarenko J., Clark J.D., Cantrell J.R., Wheeler D.K., Gabbard J.L., Hix D., Sette A., et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 2015, 43:D405-D412.
-
(2015)
Nucleic Acids Res
, vol.43
, pp. D405-D412
-
-
Vita, R.1
Overton, J.A.2
Greenbaum, J.A.3
Ponomarenko, J.4
Clark, J.D.5
Cantrell, J.R.6
Wheeler, D.K.7
Gabbard, J.L.8
Hix, D.9
Sette, A.10
-
65
-
-
84889637320
-
NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery
-
Jorgensen K.W., Rasmussen M., Buus S., Nielsen M. NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Immunology 2014, 141:18-26.
-
(2014)
Immunology
, vol.141
, pp. 18-26
-
-
Jorgensen, K.W.1
Rasmussen, M.2
Buus, S.3
Nielsen, M.4
-
66
-
-
84936751041
-
Automated benchmarking of peptide-MHC class I binding predictions
-
Trolle T., Metushi I.G., Greenbaum J.A., Kim Y., Sidney J., Lund O., Sette A., Peters B., Nielsen M. Automated benchmarking of peptide-MHC class I binding predictions. Bioinformatics 2015, 31:2174-2181.
-
(2015)
Bioinformatics
, vol.31
, pp. 2174-2181
-
-
Trolle, T.1
Metushi, I.G.2
Greenbaum, J.A.3
Kim, Y.4
Sidney, J.5
Lund, O.6
Sette, A.7
Peters, B.8
Nielsen, M.9
-
67
-
-
81255157774
-
Machine learning competition in immunology - prediction of HLA class I binding peptides
-
Zhang G.L., Ansari H.R., Bradley P., Cawley G.C., Hertz T., Hu X., Jojic N., Kim Y., Kohlbacher O., Lund O., et al. Machine learning competition in immunology - prediction of HLA class I binding peptides. J Immunol Methods 2011, 374:1-4.
-
(2011)
J Immunol Methods
, vol.374
, pp. 1-4
-
-
Zhang, G.L.1
Ansari, H.R.2
Bradley, P.3
Cawley, G.C.4
Hertz, T.5
Hu, X.6
Jojic, N.7
Kim, Y.8
Kohlbacher, O.9
Lund, O.10
-
68
-
-
0033388725
-
SYFPEITHI: database for MHC ligands and peptide motifs
-
Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
-
(1999)
Immunogenetics
, vol.50
, pp. 213-219
-
-
Rammensee, H.1
Bachmann, J.2
Emmerich, N.P.3
Bachor, O.A.4
Stevanovic, S.5
-
69
-
-
0037407113
-
Reliable prediction of T-cell epitopes using neural networks with novel sequence representations
-
Nielsen M., Lundegaard C., Worning P., Lauemoller S.L., Lamberth K., Buus S., Brunak S., Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003, 12:1007-1017.
-
(2003)
Protein Sci
, vol.12
, pp. 1007-1017
-
-
Nielsen, M.1
Lundegaard, C.2
Worning, P.3
Lauemoller, S.L.4
Lamberth, K.5
Buus, S.6
Brunak, S.7
Lund, O.8
-
70
-
-
84936746405
-
EpiToolKit - a web-based workbench for vaccine design
-
Schubert B., Brachvogel H.P., Jurges C., Kohlbacher O. EpiToolKit - a web-based workbench for vaccine design. Bioinformatics 2015, 31:2211-2213.
-
(2015)
Bioinformatics
, vol.31
, pp. 2211-2213
-
-
Schubert, B.1
Brachvogel, H.P.2
Jurges, C.3
Kohlbacher, O.4
-
71
-
-
84957108846
-
PVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens
-
Hundal J., Carreno B.M., Petti A.A., Linette G.P., Griffith O.L., Mardis E.R., Griffith M. pVAC-Seq: a genome-guided in silico approach to identifying tumor neoantigens. Genome Med 2016, 8:11.
-
(2016)
Genome Med
, vol.8
, pp. 11
-
-
Hundal, J.1
Carreno, B.M.2
Petti, A.A.3
Linette, G.P.4
Griffith, O.L.5
Mardis, E.R.6
Griffith, M.7
-
72
-
-
84928811341
-
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
-
Kreiter S., Vormehr M., van de Roemer N., Diken M., Lower M., Diekmann J., Boegel S., Schrors B., Vascotto F., Castle J.C., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015, 520:692-696.
-
(2015)
Nature
, vol.520
, pp. 692-696
-
-
Kreiter, S.1
Vormehr, M.2
van de Roemer, N.3
Diken, M.4
Lower, M.5
Diekmann, J.6
Boegel, S.7
Schrors, B.8
Vascotto, F.9
Castle, J.C.10
-
73
-
-
84862776855
-
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
-
Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
-
(2012)
Nature
, vol.482
, pp. 400-404
-
-
Matsushita, H.1
Vesely, M.D.2
Koboldt, D.C.3
Rickert, C.G.4
Uppaluri, R.5
Magrini, V.J.6
Arthur, C.D.7
White, J.M.8
Chen, Y.S.9
Shea, L.K.10
-
74
-
-
84920921528
-
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
-
Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., Ivanova Y., Hundal J., Arthur C.D., Krebber W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
-
(2014)
Nature
, vol.515
, pp. 577-581
-
-
Gubin, M.M.1
Zhang, X.2
Schuster, H.3
Caron, E.4
Ward, J.P.5
Noguchi, T.6
Ivanova, Y.7
Hundal, J.8
Arthur, C.D.9
Krebber, W.J.10
-
75
-
-
84920956731
-
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
-
Yadav M., Jhunjhunwala S., Phung Q.T., Lupardus P., Tanguay J., Bumbaca S., Franci C., Cheung T.K., Fritsche J., Weinschenk T., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515:572-576.
-
(2014)
Nature
, vol.515
, pp. 572-576
-
-
Yadav, M.1
Jhunjhunwala, S.2
Phung, Q.T.3
Lupardus, P.4
Tanguay, J.5
Bumbaca, S.6
Franci, C.7
Cheung, T.K.8
Fritsche, J.9
Weinschenk, T.10
-
76
-
-
84872841412
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma
-
van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013, 31:e439-e442.
-
(2013)
J Clin Oncol
, vol.31
, pp. e439-e442
-
-
van Rooij, N.1
van Buuren, M.M.2
Philips, D.3
Velds, A.4
Toebes, M.5
Heemskerk, B.6
van Dijk, L.J.7
Behjati, S.8
Hilkmann, H.9
El Atmioui, D.10
-
77
-
-
84880276438
-
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
-
Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013, 19:747-752.
-
(2013)
Nat Med
, vol.19
, pp. 747-752
-
-
Robbins, P.F.1
Lu, Y.C.2
El-Gamil, M.3
Li, Y.F.4
Gross, C.5
Gartner, J.6
Lin, J.C.7
Teer, J.K.8
Cliften, P.9
Tycksen, E.10
-
78
-
-
84943329717
-
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
-
Cohen C.J., Gartner J.J., Horovitz-Fried M., Shamalov K., Trebska-McGowan K., Bliskovsky V.V., Parkhurst M.R., Ankri C., Prickett T.D., Crystal J.S., et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 2015, 125:3981-3991.
-
(2015)
J Clin Invest
, vol.125
, pp. 3981-3991
-
-
Cohen, C.J.1
Gartner, J.J.2
Horovitz-Fried, M.3
Shamalov, K.4
Trebska-McGowan, K.5
Bliskovsky, V.V.6
Parkhurst, M.R.7
Ankri, C.8
Prickett, T.D.9
Crystal, J.S.10
-
79
-
-
84949730499
-
Immunogenicity of somatic mutations in human gastrointestinal cancers
-
Tran E., Ahmadzadeh M., Lu Y.C., Gros A., Turcotte S., Robbins P.F., Gartner J.J., Zheng Z., Li Y.F., Ray S., et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015, 350:1387-1390.
-
(2015)
Science
, vol.350
, pp. 1387-1390
-
-
Tran, E.1
Ahmadzadeh, M.2
Lu, Y.C.3
Gros, A.4
Turcotte, S.5
Robbins, P.F.6
Gartner, J.J.7
Zheng, Z.8
Li, Y.F.9
Ray, S.10
-
80
-
-
84904472602
-
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
-
Rajasagi M., Shukla S.A., Fritsch E.F., Keskin D.B., DeLuca D., Carmona E., Zhang W., Sougnez C., Cibulskis K., Sidney J., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124:453-462.
-
(2014)
Blood
, vol.124
, pp. 453-462
-
-
Rajasagi, M.1
Shukla, S.A.2
Fritsch, E.F.3
Keskin, D.B.4
DeLuca, D.5
Carmona, E.6
Zhang, W.7
Sougnez, C.8
Cibulskis, K.9
Sidney, J.10
-
81
-
-
84900301377
-
+ T cells in a patient with epithelial cancer
-
+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
-
(2014)
Science
, vol.344
, pp. 641-645
-
-
Tran, E.1
Turcotte, S.2
Gros, A.3
Robbins, P.F.4
Lu, Y.C.5
Dudley, M.E.6
Wunderlich, J.R.7
Somerville, R.P.8
Hogan, K.9
Hinrichs, C.S.10
-
82
-
-
84962301577
-
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
-
McGranahan N., Furness A.J., Rosenthal R., Ramskov S., Lyngaa R., Saini S.K., Jamal-Hanjani M., Wilson G.A., Birkbak N.J., Hiley C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016.
-
(2016)
Science
-
-
McGranahan, N.1
Furness, A.J.2
Rosenthal, R.3
Ramskov, S.4
Lyngaa, R.5
Saini, S.K.6
Jamal-Hanjani, M.7
Wilson, G.A.8
Birkbak, N.J.9
Hiley, C.T.10
-
83
-
-
84887277467
-
Properties of MHC class I presented peptides that enhance immunogenicity
-
Calis J.J., Maybeno M., Greenbaum J.A., Weiskopf D., De Silva A.D., Sette A., Kesmir C., Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol 2013, 9:e1003266.
-
(2013)
PLoS Comput Biol
, vol.9
, pp. e1003266
-
-
Calis, J.J.1
Maybeno, M.2
Greenbaum, J.A.3
Weiskopf, D.4
De Silva, A.D.5
Sette, A.6
Kesmir, C.7
Peters, B.8
-
84
-
-
84959881509
-
Gapped sequence alignment using artificial neural networks: application to the MHC class I system
-
Andreatta M., Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 2015.
-
(2015)
Bioinformatics
-
-
Andreatta, M.1
Nielsen, M.2
-
85
-
-
0033434080
-
Probability-based protein identification by searching sequence databases using mass spectrometry data
-
Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
-
(1999)
Electrophoresis
, vol.20
, pp. 3551-3567
-
-
Perkins, D.N.1
Pappin, D.J.2
Creasy, D.M.3
Cottrell, J.S.4
-
86
-
-
57449099865
-
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
-
Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367-1372.
-
(2008)
Nat Biotechnol
, vol.26
, pp. 1367-1372
-
-
Cox, J.1
Mann, M.2
-
87
-
-
84958064376
-
Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens
-
Kalaora S., Barnea E., Merhavi-Shoham E., Qutob N., Teer J.K., Shimony N., Schachter J., Rosenberg S.A., Besser M.J., Admon A., et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 2016.
-
(2016)
Oncotarget
-
-
Kalaora, S.1
Barnea, E.2
Merhavi-Shoham, E.3
Qutob, N.4
Teer, J.K.5
Shimony, N.6
Schachter, J.7
Rosenberg, S.A.8
Besser, M.J.9
Admon, A.10
-
88
-
-
84908540871
-
Proteogenomics: concepts, applications and computational strategies
-
Nesvizhskii A.I. Proteogenomics: concepts, applications and computational strategies. Nat Methods 2014, 11:1114-1125.
-
(2014)
Nat Methods
, vol.11
, pp. 1114-1125
-
-
Nesvizhskii, A.I.1
-
89
-
-
84890333499
-
HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity
-
Paul S., Weiskopf D., Angelo M.A., Sidney J., Peters B., Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol 2013, 191:5831-5839.
-
(2013)
J Immunol
, vol.191
, pp. 5831-5839
-
-
Paul, S.1
Weiskopf, D.2
Angelo, M.A.3
Sidney, J.4
Peters, B.5
Sette, A.6
-
90
-
-
84961323160
-
+ T cells in human melanoma
-
+ T cells in human melanoma. Nat Med 2015, 21:81-85.
-
(2015)
Nat Med
, vol.21
, pp. 81-85
-
-
Linnemann, C.1
van Buuren, M.M.2
Bies, L.3
Verdegaal, E.M.4
Schotte, R.5
Calis, J.J.6
Behjati, S.7
Velds, A.8
Hilkmann, H.9
Atmioui, D.E.10
-
91
-
-
84962246434
-
Sampling from the proteome to the HLA-DR ligandome proceeds via high specificity
-
Mommen G.P., Marino F., Meiring H.D., Poelen M.C., van Gaans-van den Brink J.A., Mohammed S., Heck A.J., van Els C.A. Sampling from the proteome to the HLA-DR ligandome proceeds via high specificity. Mol Cell Proteomics 2016.
-
(2016)
Mol Cell Proteomics
-
-
Mommen, G.P.1
Marino, F.2
Meiring, H.D.3
Poelen, M.C.4
van Gaans-van den Brink, J.A.5
Mohammed, S.6
Heck, A.J.7
van Els, C.A.8
-
92
-
-
79958769266
-
Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands
-
Mester G., Hoffmann V., Stevanovic S. Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci 2011, 68:1521-1532.
-
(2011)
Cell Mol Life Sci
, vol.68
, pp. 1521-1532
-
-
Mester, G.1
Hoffmann, V.2
Stevanovic, S.3
|